Open AccessWeight gain in people living with HIV switched to dual therapy
Author(s) -
Pilar Vizcarra,
María Jesús Vivancos,
María Jesús Pérez-Elías,
Ana Hernández Moreno,
José Luis Casado
Publication year - 2020
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000002421
Subject(s) - dolutegravir , rilpivirine , lamivudine , weight gain , darunavir , lean body mass , medicine , fat mass , human immunodeficiency virus (hiv) , cachexia , body weight , antiretroviral therapy , viral load , virology , cancer , virus , hepatitis b virus
: Changes in weight and body composition were assessed in long-term suppressed HIV-infected patients switching to dolutegravir/rilpivirine (n = 37), and compared with similar patients switching to darunavir/lamivudine (n = 17). At month 12, weight significantly increased with dolutegravir/rilpivirine (1.8 kg, IQR -1.2 to 4.1; 2.5%; P = 0.03). A follow-up DXA (median, 16 months) showed similar increases in trunk (7.8%), arms (5.6%), and legs (6.2%) fat mass, without changes in lean mass. Despite lower weight gain (0.70 kg, IQR -0.8 to 4.0, P = 0.28), fat mass increase was similar in the darunavir/lamivudine group. Baseline fat mass and CD4 counts were the only factors explaining fat mass gain.